Long-term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium.
نویسندگان
چکیده
This white paper, prepared by members of the Cardiac Safety Research Consortium (CSRC), discusses important issues regarding scientific and clinical aspects of long-term electrocardiographic safety monitoring during clinical drug development. To promote multistakeholder discussion of this topic, a Cardiac Safety Research Consortium-sponsored Think Tank was held on 2 December 2015 at the American College of Cardiology's Heart House in Washington, DC. The goal of the Think Tank was to explore how and under what circumstances new and evolving ambulatory monitoring technologies could be used to improve and streamline drug development. This paper provides a detailed summary of discussions at the Think Tank: it does not represent regulatory guidance.
منابع مشابه
Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development.
This white paper, prepared by members of the Cardiac Safety Research Consortium, discusses several important issues regarding the evaluation of ventricular arrhythmias in early clinical pharmacology trials and their potential consequences for later clinical drug development. Ventricular arrhythmias are infrequent but potentially important medical events whose occurrence in early clinical pharma...
متن کاملThe evaluation and management of drug effects on cardiac conduction (PR and QRS intervals) in clinical development.
Recent advances in electrocardiographic monitoring and waveform analysis have significantly improved the ability to detect drug-induced changes in cardiac repolarization manifested as changes in the QT/corrected QT interval. These advances have also improved the ability to detect drug-induced changes in cardiac conduction. This White Paper summarizes current opinion, reached by consensus among ...
متن کاملAssessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium.
This White Paper, prepared by members of the Cardiac Safety Research Consortium, discusses several important issues regarding the evaluation of blood pressure (BP) responses to drugs being developed for indications not of a direct cardiovascular (CV) nature. A wide range of drugs are associated with off-target BP increases, and both scientific attention and regulatory attention to this topic ar...
متن کاملCardiac safety, risk management, and oncology drug development.
Cardiac safety biomarkers are increasingly employed in the preclinical and clinical development of investigational oncology products. Irrespective of overt clinical toxicities, cardiacrelated laboratory tests can influence decision making at many levels during the conduct of clinical studies, including eligibility for protocol therapy, dose delivery or discontinuation, and analyses of optimal d...
متن کاملElectrocardiographic Indices, Circulating Electrolytes and Cardiac Enzymes of Apparently Healthy Aged Layer Hens
BACKGROUND: Staphylococcus aureus is a highly versatile pathogen of a large number of domestic ani- mals, including avian species. There is limited information about S. aureus isolated from companion and wild birds in Iran. OBJECTIVES: The aim of this study was to determine drug resistance and random-amplified polymorphic DNA-PCR (RAPD-P...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- American heart journal
دوره 187 شماره
صفحات -
تاریخ انتشار 2017